Talking About Tumors with Ryann and Ryan - A medical oncology podcast

Talking About Tumors

Designed for residents and fellows to provide an overview of the clinical practice and evidence behind management of each individual tumor site. Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, cancer

  1. 05/03/2025

    05_02 Neuroendocrine Tumors

    1. Nomenclature, unique considerations 2. Secretory Syndromes 3. Somatostatin directed therapy 4. Peptide Receptor Radionucleotide Therapy Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com.  We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.  DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015. Uptodate.com Waltham, MA: Wolters Kluwer. 1–10 1.   Kunz PL  et al. Journal of Clinical Oncology. 2023;41(7):1359-1369. doi:10.1200/JCO.22.01013/ 2.  Strosberg JR et al. Lancet Oncol. 2021;22(12):1752-1763. doi:10.1016/S1470-2045(21)00572-6 3.  Strosberg J  et al. NEJM. 2017;376(2):125-135. doi:10.1056/NEJMOA1607427/ 4.  Caplin ME et al. NEJM. 2014;371(3):224-233. doi:10.1056/NEJMOA1316158/ 5.   Caplin ME et al. Endocrine. 2021;71(2):502-513. doi:10.1007/S12020-020-02475-6.  Neuroendocrine Tumor Guidelines, ESMO. Accessed May 1, 2025. https://www.esmo.org/guidelines/guidelines-by-topic/esmo-clinical-practice-guidelines-endocrine-and-neuroendocrine-cancers 7.   Pieterman CRC  , et al. J Neuroendocrinol. Published online January 1, 2024. doi:10.1111/JNE.13468 8.   NANETS. Accessed May 1, 2025. https://nanets.net/ 9.  Rinke A et al. Results of long-term survival. Neuroendocrinology. 2016;104(1):26-32. doi:10.1159/000443612, 10. Rinke A et al. J Clin Oncol. 2009;27(28):4656-4663. doi:10.1200/JCO.2009.22.8510,   Disclosures Talking about Tumors with Ryan and Ryann is not medical advice.  We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose.  All opinions are those of whoever stated them.  We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.  Tags Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

    28 min

  2. 12/19/2024

    05_01 Hepatocellular carcinoma

    1. Etiologies and epidemiology 2. Staging and local/regional considerations 3. Systemic Therapy 4. Differences in immune checkpoint sensitivity by etiology Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com.  We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.  DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015. Uptodate.com Waltham, MA: Wolters Kluwer. 1.           Finn RS, et al. Oncologist. 2022;27(12):E938-E948. doi:10.1093/ONCOLO/OYAC183 2.           Pfister D et al. Nature 2021 592:7854. 2021;592(7854):450-456. doi:10.1038/s41586-021-03362-0 3.           Zhu AX  et al. Lancet Oncol. 2019;20(2):282-296. doi:10.1016/S1470-2045(18)30937-9 4.           Abou-Alfa GK, et al. NEJM Evidence. 2022;1(8). doi:10.1056/EVIDOA2100070 5.           Kudo M, et al. Lancet. 2018;391(10126):1163-1173. doi:10.1016/S0140-6736(18)30207-1 7.           Llovet JM, et al. NEJM. 2008;359(4):378-390. doi:10.1056/NEJMOA0708857 8.           Reig M, et al.. J Hepatol. 2022;76(3):681-693. doi:10.1016/J.JHEP.2021.11.018 9.           Cheng AL et al.  J Hepatol. 2022;76(4):862-873. doi:10.1016/j.jhep.2021.11.030 10.        Finn RS et al. NEJM. 2020;382(20):1894-1905. doi:10.1056/NEJMOA1915745/ 11.        Rose S, et al. Lancet. 2024;404(10453):656-657. doi:10.1016/S0140-6736(24)00800-6   Disclosures Talking about Tumors with Ryan and Ryann is not medical advice.  We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose.  All opinions are those of whoever stated them.  We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.  Tags Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

    32 min

  3. 10/27/2024

    04_10 Testicular Cancer II

    1. Stage II Disease 2. Overview of BEP, EP, VIP 3. Advanced, refractory disease 4. Survivorship considerations Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com.  We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.  DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015. Uptodate.com Waltham, MA: Wolters Kluwer.   1.          Pico JL et al. Ann Oncol. 2005;16(7):1152-1159. doi:10.1093/ANNONC/MDI228 2.          Adra N, et al. J Clin Oncol. 2017;35(10):1096-1102. doi:10.1200/JCO.2016.69.5395 3.          Nichols CR et al. J Clin Oncol. 1998;16(4):1287-1293. doi:10.1200/JCO.1998.16.4.1287 4.          de Wit R et al.. JCO. 1997;15(5):1837-1843. doi:10.1200/JCO.1997.15.5.1837 5.          Culine S, et al.  Ann Oncol. 2007;18(5):917-924. doi:10.1093/ANNONC/MDM062 6.          Lorch A, et al. Journal of Clinical Oncology. 2007;25(18_suppl):5086-5086. doi:10.1200/JCO.2007.25.18_SUPPL.5086 7.          Fung C, et al.. J Natl Compr Canc Netw. 2019;17(12):1557-1568. doi:10.6004/JNCCN.2019.7369   Disclosures Talking about Tumors with Ryan and Ryann is not medical advice.  We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose.  All opinions are those of whoever stated them.  We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.  Tags Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

    26 min

  4. 09/18/2024

    04_09 Testicular Cancer I

    1. Background, work up 2. Staging of seminoma and NSGCT 3. Young Adult/Adolescent Oncology 4. Management of Stage I Disease   Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com.  We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.  DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015. Uptodate.com Waltham, MA: Wolters Kluwer. 1.          Hiester A et al. Eur J Cancer. 2021;155:64-72. doi:10.1016/J.EJCA.2021.06.022 2.          Calaway AC et al. Eur Urol. 2019;76(5):607-609. doi:10.1016/j.eururo.2019.05.031 3.          Oliver RTD et al. J Clin Oncol. 2011;29(8):957-962. doi:10.1200/JCO.2009.26.4655 4.          Oliver RTD et al. Lancet. 2005;366(9482):293-300. doi:10.1016/S0140-6736(05)66984-X 5.          Joffe JK et al. JCO. 2022;40(22):2468-2478. doi:10.1200/JCO.21.01199/ 6.          Bhatia S et al.. J NCCN. 2023;21(8):851-880. doi:10.6004/JNCCN.2023.0040 7.          Stephenson A et al. J Urol. 2019;202(2):272-281. doi:10.1097/JU.0000000000000318     Disclosures Talking about Tumors with Ryan and Ryann is not medical advice.  We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose.  All opinions are those of whoever stated them.  We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.  Tags Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

    28 min

  5. 08/02/2024

    04_08 Metastatic Renal Cell Carcinoma

    1. Historical Approach (cytoreduction, IFN-a, sunitinib 2. Prognostic risk scores 3. Evidence for modern doublet regimens 4. Later line therapy Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com.  We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.  DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015. Uptodate.com Waltham, MA: Wolters Kluwer. Flanigan RC et al.  J Urol.  2004;171(3):1071-6. doi:10.1097/01.ju0000110610.61545.aeBex A et al. JAMA Oncology. 2019;5(2):164-170.  doi:10.1001/jamaoncol.2018.5545Mejean A et al. NEJM.  2018;379:417-427. doi:10.1056/NEJMoa1803675Motzer RJ et al.  NEJM.  2007;356:115-124. doi:10.1056/NEJMoa065044Rini BI et al.  NEJM.  2019;380:1116-1127. doi:10.1056/NEJMoa1816714Rini BI et al. JCO.  2023;41(17 Supp).  doi:10.1200/JCO.2023.41.17_suppl.LBA4501Kartolo et al. Urology. 2021;157:8-14. doi:10.1016/j.urology.2021.08.023Motzer RJ et al. NEJM. 2018;378:1277-1290.  doi:10.1056/NEJMoa1712126Motzer R et al.  NEJM.  2021;384:1289-1300.  doi:10.1056/NEJMoa2035716Albiges L et al.  Ann Oncol.  2023;34(2 Supp):S1329-S1330.  doi:10.1016/j.annonc.2023.10.090Jonasch E.  ASCO Annual Meeting presented May 31, 2024 in Chicago, IL  Disclosures Talking about Tumors with Ryan and Ryann is not medical advice.  We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose.  All opinions are those of whoever stated them.  We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.  Tags Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

    24 min

  6. 07/06/2024

    04_07 Localized Renal Cell Carcinoma

    1. Risk Factors and Presentation 2. Staging and Paraneoplastic syndromes 3. Localized Therapy Options and Considerations 4. Evidence and Limitations for Adjuvant Systemic Therapy   Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com.  We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.  DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015. Uptodate.com Waltham, MA: Wolters Kluwer.   1.           Tannock IF et al. Evaluating Trials of Adjuvant Therapy: Is There Benefit for People with Resected Renal Cancer? Journal of Clinical Oncology. 2023;41(15):2713-2717. doi:10.1200/JCO.23.00280/ASSET/IMAGES/LARGE/JCO.23.00280F2.JPEG 2.           Ravaud A et al. NEJM. 2016;375(23):2246-2254. doi:10.1056/NEJMOA1611406/ 3.           Pal SK et al. Lancet. 2022;400(10358):1103-1116. doi:10.1016/S0140-6736(22)01658-0 4.           Motzer RJ et al. Lancet. 2023;401(10379):821-832. doi:10.1016/S0140-6736(22)02574-0 5.           Correa AF et al. Eur Urol. 2021;80(1):20-31. doi:10.1016/J.EURURO.2021.02.025 6.           Choueiri TK et al. NEJM. 2024;390(15):1359-1371. doi:10.1056/NEJMOA2312695/ 7.           Choueiri TK et al. NEJM. 2021;385(8):683-694. doi:10.1056/NEJMOA2106391/   Disclosures Talking about Tumors with Ryan and Ryann is not medical advice.  We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose.  All opinions are those of whoever stated them.  We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.  Tags Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

    25 min

  7. 05/24/2024

    04_06 Metastatic Urothelial Cancer

    1. Immunohistochemistry of urothelial cancer 2. History of systemic therapy in advanced and metastatic disease 3. Pembrolizumab and Enfortumab Vedotin 4. Approach to second line therapy and beyond Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com.  We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.  DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015. Uptodate.com Waltham, MA: Wolters Kluwer.  1.          Powles T et al.  NEJM. 2024;390(10):875-888. doi:10.1056/NEJMOA2312117/ 2.          Powles T et al. NEJM. 2020;383(13):1218-1230. doi:10.1056/NEJMOA2002788/ 3.          Galsky MD  et al. Lancet. 2020;395(10236):1547-1557. doi:10.1016/S0140-6736(20)30230-0 4.          Powles T et al. Lancet Oncol. 2021;22(7):931-945. doi:10.1016/S1470-2045(21)00152-2 5.          van der Heijden MS et al. NEJM. 2023;389(19):1778-1789. doi:10.1056/NEJMOA2309863/ 6.          Von der Maase H et al. JCO. 2000;18(17):3068-3077. doi:10.1200/JCO.2000.18.17.3068/ 7.          von der Maase H et al. JCO. 2023;41(23):3881-3890. doi:10.1200/JCO.22.02763 8.          Vuky J et al. . JCO. 2020;38(23):2658-2666. doi:10.1200/JCO.19.01213   Disclosures Talking about Tumors with Ryan and Ryann is not medical advice.  We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose.  All opinions are those of whoever stated them.  We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.  Tags Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

    25 min

  8. 04/20/2024

    04_05 Muscle Invasive Bladder Cancer

    1.  Etymology, presentation, and work-up of bladder/urothelial cancer 2. Role of perioperative systemic therapy 3. Tri-modality therapy (bladder sparing approach) 4. Considerations for upper tract urothelial cancer  Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com.  We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice. DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015. Uptodate.com Waltham, MA: Wolters Kluwer. 1.           Bellmunt J et al. Lancet Oncol. 2021;22(4):525-537. doi:10.1016/S1470-2045(21)00004-8 2.           Birtle AJ et al. JCO. Published online February 13, 2024. doi:10.1200/JCO.23.01659 3.           Birtle A  et al. Lancet. 2020;395(10232):1268-1277. doi:10.1016/S0140-6736(20)30415-3 4.           Bajorin DF et al. NEJM. 2021;384(22):2102-2114. doi:10.1056/NEJMOA2034442/ 5.           James ND et al. NEJM. 2012;366(16):1477-1488. doi:10.1056/NEJMOA1106106/ 6.           Pfister C et al. JCO 2023;41(17_suppl) doi:10.1200/JCO.2023.41.17_SUPPL.LBA4507 7.           Pfister C et al. Eur Urol. 2021;79(2):214-221. doi:10.1016/J.EURURO.2020.08.024 8.           Grossman HB et al. NEJM. 2003;349(9):859-866. doi:10.1056/NEJMOA022148/   Disclosures Talking about Tumors with Ryan and Ryann is not medical advice.  We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose.  All opinions are those of whoever stated them.  We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.  Tags Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

    29 min
See All (50)

4.4
out of 5
5 Ratings

About

Designed for residents and fellows to provide an overview of the clinical practice and evidence behind management of each individual tumor site. Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, cancer

Information